Journal Scans
Weekly Standard Doses of rh-EPO Are Highly Effective for the Treatment of Anemic Patients With Low-Intermediate 1 Risk Myelodysplastic Syndromes
Standard rHEPO Dose Effective for Anemia in Lower-Risk MDS
E Balleari, M Clavio, E Arboscello, A Bellodi, A Bruzzone, L Del Corso, MV Lucchetti, M Miglino, C Passalia, I Pierri, I Ponassi, C Oneto, O Racchi, M Scudeletti, L Vignolo, G Zoppoli, M Gobbi, R Ghio
20111001
2011 Nov 1
Leuk Res
Weekly Standard Doses of rh-EPO Are Highly Effective for the Treatment of Anemic Patients With Low-Intermediate 1 Risk Myelodysplastic Syndromes
Leuk Res. 2011 Nov 1;35(11):1472-1476, E Balleari, M Clavio, E Arboscello, A Bellodi, A Bruzzone, L Del Corso, MV Lucchetti, M Miglino, C Passalia, I Pierri, I Ponassi, C Oneto, O Racchi, M Scudeletti, L Vignolo, G Zoppoli, M Gobbi, R Ghio
TAKE-HOME MESSAGE
Abstract
Abstract
For more than 20 years erythropoietin (rHEPO) has largely been used to treat anemia in myelodysplastic syndromes (MDS). Early clinical trials showed erythroid responses in no more than 15–25% of patients. In the last decade, a better selection of MDS patients suitable for a therapeutic challenge with rHEPO,alone or in combination with G-CSF, allowed for an increased response-rate, averaging around 40%. More recently, an even higher percentage of responses have been obtained using higher-doses of...
